Literature DB >> 25630815

The immunogenicity of antibody aggregates in a novel transgenic mouse model.

Juliana Bessa1, Sabine Boeckle, Hermann Beck, Thomas Buckel, Sonja Schlicht, Martin Ebeling, Anna Kiialainen, Atanas Koulov, Björn Boll, Thomas Weiser, Thomas Singer, Antonius G Rolink, Antonio Iglesias.   

Abstract

PURPOSE: Protein aggregates have been discussed as a potential risk factor related to immunogenicity. Here we developed a novel human IgG transgenic (tg) mouse system expressing a mini-repertoire of human IgG1 antibodies (Abs) for the assessment of immunogenic properties of human mAb preparations.
METHODS: Transgenic mice were generated using germline versions of the human Ig heavy chain γ1 (IgH-γ1), and the human Ig light chain (IgL) κ and λ genes. Only the soluble form of human IgH-γ1 was used to avoid expression of the membrane Ig-H chain and concomitant allelic exclusion of endogenous murine Ig genes. IgG1 aggregates were generated by different stress conditions such as process-related, low pH and exposure to artificial light.
RESULTS: The expression of human Ig proteins induced immunological tolerance to a broad range of human IgG1 molecules in the tg mice. Immunization with IgG1 aggregates demonstrated that soluble oligomers induced by significant light-exposure and carrying neo-epitopes induced a strong immune response in tg mice. In contrast, Ab aggregates alone and monomers with neo-epitopes were not immunogenic.
CONCLUSION: This mouse model is able to recognize immunogenic modifications of human IgG1. While the degree of stress-induced aggregation varies for different mAbs, our findings using a particular mAb (mAb1) demonstrate that non-covalently modified aggregates do not break tolerance, contrary to widely held opinion. The immunogenic potential of soluble aggregates of human IgG strongly depends on the presence of neo-epitopes resulting from harsh stress conditions, i.e. extensive exposure to artificial light.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25630815     DOI: 10.1007/s11095-015-1627-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  62 in total

Review 1.  B-cell tolerance.

Authors:  C C Goodnow
Journal:  Curr Opin Immunol       Date:  1992-12       Impact factor: 7.486

Review 2.  Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.

Authors:  Anne S De Groot; Julie McMurry; Lenny Moise
Journal:  Curr Opin Pharmacol       Date:  2008-09-19       Impact factor: 5.547

3.  Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.

Authors:  Miranda M C Van Beers; Francesca Gilli; Huub Schellekens; Theodore W Randolph; Wim Jiskoot
Journal:  J Pharm Sci       Date:  2011-09-14       Impact factor: 3.534

4.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

Authors:  X D Yang; X C Jia; J R Corvalan; P Wang; C G Davis; A Jakobovits
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

5.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

6.  The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans.

Authors:  M L Gallo; V E Ivanov; A Jakobovits; C G Davis
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

7.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice.

Authors:  M J Mendez; L L Green; J R Corvalan; X C Jia; C E Maynard-Currie; X D Yang; M L Gallo; D M Louie; D V Lee; K L Erickson; J Luna; C M Roy; H Abderrahim; F Kirschenbaum; M Noguchi; D H Smith; A Fukushima; J F Hales; S Klapholz; M H Finer; C G Davis; K M Zsebo; A Jakobovits
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

8.  Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

Authors:  Vivian Bi; Vibha Jawa; Marisa K Joubert; Arunan Kaliyaperumal; Catherine Eakin; Karen Richmond; Oscar Pan; Jilin Sun; Martha Hokom; Theresa J Goletz; Jette Wypych; Lei Zhou; Bruce A Kerwin; Linda O Narhi; Taruna Arora
Journal:  J Pharm Sci       Date:  2013-08-07       Impact factor: 3.534

9.  High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

Authors:  D M Fishwild; S L O'Donnell; T Bengoechea; D V Hudson; F Harding; S L Bernhard; D Jones; R M Kay; K M Higgins; S R Schramm; N Lonberg
Journal:  Nat Biotechnol       Date:  1996-07       Impact factor: 54.908

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  26 in total

Review 1.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

2.  Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

Authors:  Austin L Daniels; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2018-02-01       Impact factor: 3.534

3.  Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Authors:  E M Moussa; J Kotarek; J S Blum; E Marszal; E M Topp
Journal:  Pharm Res       Date:  2016-04-01       Impact factor: 4.200

4.  Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.

Authors:  Friederike Plath; Philippe Ringler; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Melissa A Graewert; Dmitri Svergun; Gerald Gellermann; Christof Finkler; Jan O Stracke; Atanas Koulov; Volker Schnaible
Journal:  MAbs       Date:  2016-03-31       Impact factor: 5.857

5.  A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.

Authors:  Geetha Thiagarajan; Andrew Semple; Jose K James; Jason K Cheung; Mohammed Shameem
Journal:  MAbs       Date:  2016-05-21       Impact factor: 5.857

6.  Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.

Authors:  Linda O Narhi; Quanzhou Luo; Jette Wypych; Riccardo Torosantucci; Andrea Hawe; Kiyoshi Fujimori; Yasser Nashed-Samuel; Vibha Jawa; Marisa K Joubert; Wim Jiskoot
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

7.  Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice.

Authors:  Matthieu Piccand; Juliana Bessa; Eginhard Schick; Claudia Senn; Carole Bourquin; Wolfgang F Richter
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

Review 8.  Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Authors:  Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi
Journal:  J Pharm Sci       Date:  2016-04-01       Impact factor: 3.534

9.  Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods.

Authors:  Heesu Chae; Seulki Cho; Munsik Jeong; Kiyoung Kwon; Dongwook Choi; Jaeyoung Lee; Woosuk Nam; Jisu Hong; Jiwoo Lee; Seonjoo Yoon; Hyojeong Hong
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 10.  Protein aggregation and immunogenicity of biotherapeutics.

Authors:  Ngoc B Pham; Wilson S Meng
Journal:  Int J Pharm       Date:  2020-06-09       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.